FDA 安全性情報/クラリスロマイシン

FDA Drug Safety Communication: FDA review finds additional data supports the potential for increased long-term risks with antibiotic clarithromycin (Biaxin) in patients with heart disease (URL)

出典)FDA >Drug Safety and Avalilability (URL)